Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02251821 · ClinicalTrials.gov registry record · Phase 2
JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
A Phase 2 study of Primary Myelofibrosis and Secondary Myelofibrosis, sponsored by Fred Hutchinson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
- 1
- Study location
NCT02251821 is a Phase 2 study of Primary Myelofibrosis and Secondary Myelofibrosis that is active but no longer recruiting, run by Fred Hutchinson Cancer Center. The registered enrollment target is 61 participants, below the 119-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02251821, a Phase 2 study of Primary Myelofibrosis and Secondary Myelofibrosis, is active but no longer recruiting, sponsored by Fred Hutchinson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well giving a JAK inhibitor before a donor stem cell transplant works in treating patients with myelofibrosis that developed without another condition (primary) or evolved from other bone marrow disorders (secondary). JAK inhibitors are a class of drugs that may stop the growth of abnormal cells by blocking an enzyme needed for cell growth. Giving a JAK inhibitor such as ruxolitinib before a donor stem cell transplant may help reduce symptoms of myelofibrosis such as inflammation and enlargement of the spleen, improve the patient's general physical condition, and prevent complications from occurring after the transplant. Infusing healthy stem cells from a donor into the patient may help the patient's bone marrow work normally and make stem cells, red blood cells, white blood cells, and platelets. Giving a JAK inhibitor before a donor stem cell transplant may help improve transplant outcomes in patients with myelofibrosis.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Busulfan
- OTHER Laboratory Biomarker Analysis
- DRUG Fludarabine Phosphate
- PROCEDURE Allogeneic Hematopoietic Stem Cell Transplantation
Study Locations (1)
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2014-10-20 |
| Est. Completion | 2025-12-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02251821
The ClinicalTrials.gov registry entry for NCT02251821 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (49% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Primary Myelofibrosis appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02251821 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT02251821 about?
NCT02251821 is a clinical study titled "JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis". This phase II trial studies how well giving a JAK inhibitor before a donor stem cell transplant works in treating patients with myelofibrosis that developed without another condition (primary) or evolved from other bone marrow disorders (secondary). JAK inhibitors are a class of drugs that may stop ...
What is the current status of trial NCT02251821?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2014-10-20. Estimated completion is 2025-12-28.
What conditions does trial NCT02251821 study?
This clinical trial studies the following conditions: Primary Myelofibrosis, Secondary Myelofibrosis.
What interventions are being tested in trial NCT02251821?
The interventions under investigation include: Cyclophosphamide (DRUG), Busulfan (DRUG), Laboratory Biomarker Analysis (OTHER), Fludarabine Phosphate (DRUG), Allogeneic Hematopoietic Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT02251821?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02251821 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
RECRUITING · Phase 2
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Study of Canakinumab in Patients With Myelofibrosis
RECRUITING · Phase 2
-
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
RECRUITING · Phase 2
-
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
RECRUITING · Phase 2
-
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.